Two clones of mouse-human hybridomas, secreting human monoclonal antibodies to a peanut allergen Ara h1, were generated from human peripheral blood lymphocytes transformed with Epstein--Barr virus, followed by cell fusion with mouse myeloma cells. Epitope analysis with overlapping peptides synthesized on a multi-pin apparatus revealed antibody-binding sequences of Ara h1 protein.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3449475 | PMC |
| http://dx.doi.org/10.1007/s10616-005-1578-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid.
J Alzheimers Dis
May 2023
Neuroscience Department, Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Background: Clearance of tau seeds by immunization with tau antibodies is currently evaluated as therapeutic strategy to block the spreading of tau pathology in Alzheimer's disease and other tauopathies. Preclinical evaluation of passive immunotherapy is performed in different cellular culture systems and in wild-type and human tau transgenic mouse models. Depending on the preclinical model used, tau seeds or induced aggregates can either be of mouse, human or mixed origin.
View Article and Find Full Text PDFHighly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development.
Sci Rep
October 2022
Center of Excellence in Systems Biology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Article Synopsis
- PD-1 is a key protein that helps to suppress the immune response against tumors, making it a critical target for cancer treatments called immune checkpoint inhibitors (ICIs).
- Researchers developed a new strategy to create effective chimeric anti-PD-1 molecules, which combine features from different sources to improve cancer therapy.
- The new chimeric antibodies created demonstrated strong ability to bind to PD-1, activating T cells similarly to existing treatments, marking them as promising candidates for future immunotherapy development.
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
EBioMedicine
February 2022
AXON Neuroscience R&D Services SE; Bratislava, 811 02, Slovakia; Institute of Neuroimmunology, Slovak Academy of Sciences; Bratislava, 845 10, Slovakia.
Background: The emergence of new SARS-CoV-2 variants of concern B.1.1.
View Article and Find Full Text PDFAnti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.
Sci Rep
January 2020
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Article Synopsis
- Anti-D immunoglobulin (Anti-D Ig) is crucial for preventing hemolytic disease in newborns, and monoclonal IgG anti-Ds (mAb-Ds) show promise for unlimited supply but vary in effectiveness.
- Research analyzed the glycosylation features of various mAb-Ds and found that differences, particularly in fucosylation, significantly impacted their ability to clear red blood cells and prevent immune responses compared to traditional anti-D Ig.
- The study suggests that mAb-Ds with high galactosylation and low fucosylation may enhance red cell clearance at lower doses, leading to effective and cost-efficient prophylaxis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!